Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: Protease inhibitor-mediated neurotoxicity

Keyphrases

• Neurotoxicity 100%
• Protease Inhibitors 100%
• Human Immunodeficiency Virus/acquired Immunodeficiency Syndrome 100%
• Sensory Neuropathy 100%
• AIDS/HIV 70%
• HIV Patients 50%
• Indinavir 30%
• Antiretroviral Therapy 20%
• Macrophages 20%
• Dorsal Root Ganglion Culture 20%
• Risk Factors 10%
• Clinical Features 10%
• C-C Chemokine Receptor Type 5 (CCR5) 10%
• Dorsal Root Ganglion 10%
• Neuronal Damage 10%
• Neuronal Injury 10%
• Didanosine 10%
• Transgenic 10%
• Patient-assessed 10%
• Plasma Viral Load 10%
• Trophic Factors 10%
• Neurological Diseases 10%
• Ritonavir 10%
• Saquinavir 10%
• Viral Exposure 10%
• Neurite Retraction 10%
• Antiretroviral Toxic Neuropathy 10%
• Pathogenic Determinants 10%
• Neuronal Atrophy 10%
• Process Loss 10%

Medicine and Dentistry

• Neurotoxicity 100%
• Human Immunodeficiency Virus 100%
• Acquired Immune Deficiency Syndrome 100%
• Proteinase Inhibitor 100%
• Sensory Neuropathy 100%
• Dorsal Root Ganglion 23%
• Indinavir 23%
• Macrophage 15%
• Antiretroviral Therapy 15%
• Disease 7%
• Injury 7%
• Clinical Feature 7%
• Neurologic Disease 7%
• Exposure Therapy 7%
• Didanosine 7%
• Neuropathy 7%
• Ritonavir 7%
• Saquinavir 7%
• Trophic Factor 7%
• 2',3' Dideoxynucleoside Derivative 7%
• Neurite 7%

Neuroscience

• Human Immunodeficiency Virus 100%
• Peripheral Neuropathy 100%
• Neurotoxicity 100%
• Proteinase 100%
• Dorsal Root Ganglion 23%
• Indinavir 23%
• Macrophage 15%
• CD4 7%
• Exposure Therapy 7%
• Didanosine 7%
• Neurite 7%
• Nervous System Disorder 7%
• CCR5 7%
• 2',3' Dideoxynucleoside Derivative 7%
• Ritonavir 7%
• Saquinavir 7%